Search company, investor...
BioHorizons company logo

BioHorizons

biohorizons.com

Founded Year

1994

Stage

Recap | Alive

Total Raised

$52.5M

Valuation

$0000 

Last Raised

$145M | 9 yrs ago

Revenue

$0000 

About BioHorizons

BioHorizons is a provider in advanced dental implant technologies and tissue regeneration products in the dental implant industry. The company, based in Birmingham, Alabama, offers a broad spectrum of products for the replacement of missing teeth including dental implants, restorative and laboratory components, soft and hard tissue biologic products, and surgical planning software. BioHorizons' unique dental implant designs are recognized for intuitive design, excellent primary stability, and high-end, esthetic outcomes through the use of BioHorizons' Laser-Lok microchannel surface technology. Laser-Lok has been shown to uniquely achieve both bone and soft tissue attachment for long-term tissue maintenance. The company has six international subsidiaries and more than 50 distributors around the world.

Headquarters Location

2300 Riverchase Center

Birmingham, Alabama, 35244,

United States

205-967-7880

Missing: BioHorizons's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BioHorizons's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing BioHorizons

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioHorizons is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

D

Dental Health

959 items

Companies delivering dental care products and services. Excludes practice networks.

BioHorizons Patents

BioHorizons has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/22/2013

Surgical instruments, Dentistry, Implants (medicine), Prosthetics, Neurosurgery

Application

Application Date

10/22/2013

Grant Date

Title

Related Topics

Surgical instruments, Dentistry, Implants (medicine), Prosthetics, Neurosurgery

Status

Application

Latest BioHorizons News

Bone Graft and Substitutes Market will reach to USD 5.78 billion by 2030 : GreyViews

Jan 3, 2023

Major Players AlloSource, Baxter, Johnson & Johnson Services, Inc., Smith & Nephew, Stryker, Orthofix Medical Inc., Zimmer Biomet, Medtronic, Geistlich Pharma AG, Dentsply Sirona, Biobank, Wright Medical Group N.V., Globus Medical, BioHorizons, Integra LifeSciences, Arthrex, Inc., Artoss, Inc., ACE Surgical Supply Co., Inc., ACE Surgical Supply Co., Inc., Institut Straumann AG and NuVasive, Inc., among other Segmentation Analysis The allograft segment is expected to be the fastest-growing segment in 2022. The type segment is an allograft, synthetic, Demineralized Bone Matrix (DMI), and xenograft. The allograft segment is expected to witness the highest growth rate during the forecast period. Due to the benefits of allografts, such as high osteo conductivity and quick structural support, their utilization is rising. Additionally, they don't require a second operation, which shortens the surgical procedure and speeds up wound healing. These are regularly used on the spine, hip, and knee. Demineralized bone matrices are available in a range of dimensions and forms, including chips, pellets, and granules. They also have osteoinductive and osteoconductive properties, which adds to their appeal and the expansion of the market. The spinal fusion segment is expected to be the fastest-growing segment in 2022. The application segment is dental, foot and ankle, long bone, craniomaxillofacial, joint reconstruction, and spinal fusion. The spinal fusion segment is expected to witness the highest growth rate during the forecast period. The development can be attributed to an increase in spondylosyndesis surgeries utilizing bone transplant materials. Additionally, the need for corrective surgery is rising due to the aging population, which is more prone to orthopedic disorders. This is anticipated to hasten market expansion in the near future. Between 2015 and 2050, the senior population is expected to double, from 12% to 22%, according to the World Health Organization. The segment is expected to benefit significantly from growing graft utilization for dental procedures over the course of the forecast period. The grafts are often used as a scaffold and filler to hasten healing and aid in the formation of new bone. The hospital segment is expected to be the fastest-growing segment in 2022. The end-user segment is hospitals, specialty clinics, and others. The hospital segment is expected to witness the highest growth rate during the forecast period. The segmental growth is attributed to hospitals' extensive use of orthopedists. Throughout the forecast period, it is also anticipated that more patients would visit hospitals to select from a range of spine and joint reconstructive procedures. For instance, a Healthline Media story from April 2020 reports that total knee replacement surgery is now often carried out at numerous facilities, with an estimated 600,000 procedures carried out a year. Regional Analysis            The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the bone graft and substitutes include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia. The North America region witnessed a major share. The main factors influencing regional market growth are rising awareness of novel goods that are commercially available, accessibility to a highly developed healthcare system, and greater healthcare spending of 16.9% in 2018. Due to the rising incidence of orthopedic diseases and trauma-related injuries, the American market is outpacing both the North American and global markets by creating the highest demand for bone grafts and substitutes. Country Analysis Germany Germany's bone graft and substitutes market size was valued at USD 0.0051 billion in 2022 and is expected to reach USD 0.0074 billion by 2030, at a CAGR of 4.8% from 2023 to 2030. The growing number of strategic initiatives, such as product launches, approvals, acquisitions, mergers, partnerships, and joint ventures, is expected to improve regional growth. China China’s bone graft and substitutes market size was valued at USD 0.0071 billion in 2022 and is expected to reach USD 0.0110 billion by 2030, at a CAGR of 5.7% from 2023 to 2030. Rising healthcare expenses, more understanding of commercially available technology, and accessibility to an extensive healthcare system are the three key factors influencing the region's growth. India India's Bone graft and substitutes market size was valued at USD 0.0063 billion in 2022 and is expected to reach USD 0.0093 billion by 2030, at a CAGR of 5% from 2023 to 2030. Emerging nations like India focus on constructing medical facilities like specialty clinics in order to handle a larger patient pool. Long-term market growth is predicted to be supported by the focused focus on improving healthcare infrastructure. Covid-19 Impact Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries. Furthermore, the growth of the bone graft and substitutes market is mainly driven owing to the rising demand for dental bone grafts. Buy Now Full Report @ https://greyviews.com/checkout/247/single_user_license Contact Us

BioHorizons Frequently Asked Questions (FAQ)

  • When was BioHorizons founded?

    BioHorizons was founded in 1994.

  • Where is BioHorizons's headquarters?

    BioHorizons's headquarters is located at 2300 Riverchase Center, Birmingham.

  • What is BioHorizons's latest funding round?

    BioHorizons's latest funding round is Recap.

  • How much did BioHorizons raise?

    BioHorizons raised a total of $52.5M.

  • Who are the investors of BioHorizons?

    Investors of BioHorizons include Henry Schein, Piper Sandler, Deerfield Management, DTI Dental Technologies, HealthpointCapital and 3 more.

  • Who are BioHorizons's competitors?

    Competitors of BioHorizons include Active Implants, Healionics, Neoss, Wright Medical Group, Cagenix, CardiAQ Valve Technologies, The Foundry Visionmongers, Ocular Therapeutix, Conceptus, TransCorp and 16 more.

Compare BioHorizons to Competitors

D
Dental Implants

Dental Implant Technologies (DIT) is a San Antonio based dental technology company providing an end to end suite of integrated implant based restorative services and products for dental patients requiring the replacement of most or all of their teeth. In the United States alone this market includes 30M individuals or a served addressable market of $96B including $26B for DIT's products and services.

Active Implants Logo
Active Implants

Active Implants develops orthopedic implant solutions that complement the natural biomechanics of the musculoskeletal system, allowing patients to maintain or return to an active lifestyle.

Cagenix Logo
Cagenix

Cagenix develops and researches new devices for dental implants. The company's main focus is on providing superstructures for multiple dental implants that is used to restore chewing function and aesthetics for patients.

B
Biophan Technologies

Biophan is dedicated to providing technologies that offer innovative andcompetitive advantages to the medical device industry. The Company ishelping to commercialize the Myotech Circulatory Support System, which has potential to improve the treatment of acute heart failure.Biophan Technologies, Inc. holds a 68% interest in Myotech. Biophan istraded on the OTC market under the symbol BIPH, and is also listed on theFrankfurt Stock Exchange under the symbol BTN.

I
Intelligent Orthopaedics

Intelligent Orthopaedics, the designers of STORM (The staffordshire orthopaedic reduction machine) for the reduction of tibial fractures and IOS the flexible, single use fixator

Biomedical Implant Technology Logo
Biomedical Implant Technology

Biomedical Implant Technology aims to provide dental implant training programs and a patented, one-piece, one-stage implant system.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.